Dupixent Pre-filled Syringe works by blocking two specific proteins of the immune system — IL-4 and IL-13. They are responsible for triggering inflammation in eczema, asthma, and nasal polyps. By blocking the function of these proteins, Dupixent alleviates the inflammation responsible for causing symptoms of these diseases.
- IL-4 and IL-13: These two proteins have been said to be behind allergic reactions and chronic inflammation. By reducing their activity, Dupixent manages and stabilizes the inflammation at its root, preventing flare-ups and reducing the severity of symptoms.
- Dupilumab: Dupilumab, the active substance in Dupixent, is specifically engineered to target IL-4 and IL-13, offering a targeted way of managing inflammation in eczema and asthma conditions, thus making it easier for the patient to manage their chronic condition.
- The Dupixent Pre-filled Syringe ensures that patients inject the proper, consistent dose with each injection.